Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
61-80 of 936 trials

Methylmalonic Acidemia: mRNA-3705 Treatment Study

We are testing a new treatment, mRNA-3705, for individuals with isolated Methylmalonic Acidemia. The study aims to evaluate its safety and how well it lowers harmful acid levels in the blood.

Methylmalonic Aciduria>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Myelofibrosis and Essential Thrombocythemia: INCA033989 Study

We are evaluating the effects and safety of a new treatment called INCA033989 for individuals with myelofibrosis or essential thrombocythemia. This study aims to understand how well it works compared to current options.

Myeloproliferative Neoplasms>2 yearsSafety phase (I)HematologyOncology

Solid Tumors: AZD5335 Treatment Study

We are investigating the safety and effectiveness of AZD5335, both alone and with other treatments, for people with solid tumors. This study will help us understand how the drug works in the body.

Platinum-resistant Recurrent Ovarian CancerPlatinum-sensitive Recurrent Ovarian CancerLung Adenocarcinoma>2 yearsSafety phase (I)Oncology

Acute Myeloblastic Leukemia: Daratumumab with Chemotherapy

We are testing a new treatment combining daratumumab with chemotherapy for patients aged 60 and older with adverse risk acute myeloblastic leukemia. The goal is to see if this combination is safe and effective.

Acute Myeloblastic Leukemia>2 yearsSafety phase (I)HematologyOncology

Systemic Lupus Erythematosus: RO7507062 Study

We are investigating a new medication for people with systemic lupus erythematosus to see how safe it is and how the body responds to it. This study aims to gather important information for future treatments.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Internal MedicineRheumatology

Durvalumab After Chemo and Radiation for Lung Cancer

We are investigating how well Durvalumab works for patients with non-small cell lung cancer after they receive chemotherapy and radiation. This study includes both PDL1 positive and negative patients to see how their responses differ.

Non-small Cell Lung CancerSafety phase (I)Efficacy phase (II)Oncology

Advanced Solid Tumors: TNG462 Treatment Study

We are testing a new treatment called TNG462 for patients with advanced solid tumors that have a specific genetic deletion. The study aims to evaluate its safety and effectiveness, both alone and with another medication.

Advanced or Metastatic Solid Tumors with MTAP Deletion>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Perianal Fistulas: Regenerative Cell Therapy Study

We are evaluating a new treatment combining surgery and regenerative cell therapy for people with complex perianal fistulas. The goal is to see if this approach improves healing outcomes.

Perianal Fistula>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGastroenterology

Non-Hodgkin Lymphoma: GLPG5101 Treatment Study

We are evaluating a new treatment called GLPG5101 for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aims to understand its safety and effectiveness compared to existing options.

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

IMC-F106C for Advanced PRAME-Positive Cancers

We are studying a new treatment called IMC-F106C for individuals with advanced PRAME-positive cancers. The trial aims to assess its safety and effectiveness, both alone and with other cancer therapies.

Urothelial CarcinomaNon-Small Cell Lung CancerOvarian Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Cancer Study: LY3537982 for KRAS G12C Mutant Tumors

We are testing a new drug, LY3537982, in patients with advanced solid tumors that have a specific genetic mutation. The goal is to see how well it works and how safe it is when used alone or with other cancer treatments.

KRAS G12C-Mutant Advanced Solid TumorsSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: ADU-1805 Treatment Study

We are testing a new treatment called ADU-1805 for adults with advanced solid tumors. The study aims to evaluate its safety and how the body handles the medication.

Advanced Cancer1-2 yearsSafety phase (I)Oncology

Advanced Cancer: AZD8205 Treatment Study

We are studying the safety and early effectiveness of AZD8205, both alone and with other cancer treatments, for people with advanced or metastatic solid tumors. This research aims to find the best dose and understand how the drug works in the body.

Breast CancerOvarian CancerEndometrial CancerSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

B-Cell Malignancies: CAR-T Cell Therapy Study

We are testing a new CAR-T cell treatment for patients with relapsed and refractory B-cell cancers. The goal is to find a safe dose and understand how well it works.

Diffuse Large B-Cell LymphomaMultiple Myeloma1-2 yearsSafety phase (I)HematologyOncology

Fibrolamellar Hepatocellular Carcinoma: DNAJB1-PRKACA Vaccine

We are testing a new peptide vaccine for patients with fibrolamellar hepatocellular carcinoma and other tumors with a specific genetic fusion. This study aims to see if it works better when combined with immune checkpoint therapy.

Tumor with DNAJB1-PRKACA FusionFibrolamellar Hepatocellular CarcinomaSafety phase (I)HepatologyOncology

Favipiravir: High Dose Tolerance Study

We are evaluating how well healthy volunteers tolerate a high dose of favipiravir. This study will help us understand the drug's effects on the body.

Healthy Volunteers>2 yearsSafety phase (I)Infectious Diseases

Wilson Disease: UX701 Gene Therapy Study

We are evaluating a new gene therapy for adults with Wilson disease to see if it safely helps manage copper levels in the body. The study will also look at how it affects the need for current medications and overall liver health.

Wilson's Disease1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInfectious DiseasesInternal Medicine

Pulmonary Sarcoidosis: XTMAB-16 Treatment Study

We are testing a new treatment called XTMAB-16 for people with pulmonary sarcoidosis to see if it can safely reduce the need for corticosteroids. This study will help determine the best dose and assess its effectiveness.

Pulmonary Sarcoidosis3-6 monthsSafety phase (I)Efficacy phase (II)>20 visitsInvestigational MedicinesInternal MedicinePulmonology

Propionic Acidemia: mRNA-3927 Treatment Study

We are investigating the safety and effectiveness of mRNA-3927 in individuals with propionic acidemia. The study aims to see if this treatment can reduce serious health events related to the condition.

Propionic AcidemiaSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyInternal Medicine

PARP-PET Imaging in Solid Tumors

We are exploring how PARP-PET imaging can help in diagnosing and monitoring solid tumors. This study aims to see if it provides better insights compared to standard imaging methods.

Castration-Resistant Prostate CancerMetastatic Breast CancerMetastatic Ovarian Cancer>2 yearsSafety phase (I)Oncology